TABLE 4.

EKs and antifungal susceptibilities of sequential C. parapsilosis isolates from patients whose fungemia was recurrent even after CVC removal

Patient no. and isolate no.	Date of isolation (mo/day/yr)	MICa (μg/ml)			Karyotype
		AmB	Flu	Itra
10
10-0	12/09/96	0.5	0.25	0.06	l
10-1	12/10/96	0.5	0.25	0.06	l
10-9	12/18/96	0.5	0.25	0.06	l
10-12	12/21/96	0.5	0.25	0.06	l
11
11-0	06/09/99	0.5	1.0	0.06	m
11-52	07/31/99	0.5	0.5	0.06	n
11-68	08/16/99	0.5	0.5	0.06	n
11-78	08/26/99	0.5	0.5	0.06	n
12
12-0	07/15/99	0.5	0.5	0.06	o
12-35	08/19/99	0.5	0.5	0.06	o
12-53	09/06/99	0.5	0.5	0.06	o
12-61	09/14/99	0.5	0.5	0.06	o
12-67	09/20/99	0.5	0.5	0.06	o
13
13-0	09/13/99	0.5	0.25	0.03	p
13-14	09/27/99	1.0	0.5	0.06	q
13-18	10/01/99	1.0	0.5	0.06	q
13-38	10/21/99	1.0	0.5	0.06	q
14
14-4	06/05/97	0.5	0.25	0.03	r
14-158	11/10/97	0.5	0.5	0.03	s
15
15-0	09/26/97	0.5	0.5	0.03	t
15-27	10/23/97	0.5	0.25	0.03	u
16
16-0	02/04/99	1.0	0.5	0.25	v
16-23	02/27/99	1.0	0.5	0.25	w
17
17-0	09/06/99	1.0	1.0	0.25	x
17-11	09/17/99	0.5	0.5	0.06	y

^aAmB, amphotericin B; Flu, fluconazole; Itra, itraconazole.